Rapamycin nanoparticles localize in diseased lung vasculature and prevent pulmonary arterial hypertension

This study demonstrates the potential for nanoparticles to significantly impact PAH through site-specific delivery of therapeutics. Graphical abstract
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research